Tacrolimus versus anti-tumor necrosis factor agents for steroid-refractory active ulcerative colitis based on the severity of endoscopic findings: a single-center, open-label cohort study

Satohiro MatsumotoDepartment of Gastroenterology, Saitama Medical Center, Jichi Medical University, Saitama, Saitama, JapanCorrespondence[email protected]

Haruna KawamuraDepartment of Gastroenterology, Saitama Medical Center, Jichi Medical University, Saitama, Saitama, Japan

Takeshi NishikawaDepartment of Gastroenterology, Saitama Medical Center, Jichi Medical University, Saitama, Saitama, Japan

Noriyoshi SagiharaDepartment of Gastroenterology, Saitama Medical Center, Jichi Medical University, Saitama, Saitama, Japan

Hiroyuki MiyataniDepartment of Gastroenterology, Saitama Medical Center, Jichi Medical University, Saitama, Saitama, Japan

Hirosato MashimaDepartment of Gastroenterology, Saitama Medical Center, Jichi Medical University, Saitama, Saitama, Japan

Pages 249-258 | Published online: 26 Sep 2017

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

FaubionWAJrLoftusEVJrHarmsenWSZinsmeisterARSand-bornWJThe natural history of corticosteroid therapy for inflammatory bowel disease: a population-based studyGastroenterology2001121225526011487534
PubMed Web of Science ®Google Scholar
OgataHMatsuiTNakamuraMA randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitisGut20065591255126216484504
PubMed Web of Science ®Google Scholar
BaumgartDCPintofflJPSturmAWiedenmannBDignassAUTacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease–a long-term follow-upAm J Gastroenterol200610151048105616573777
PubMed Web of Science ®Google Scholar
RutgeertsPSandbornWJFeaganBGInfliximab for induction and maintenance therapy for ulcerative colitisN Engl J Med2005353232462247616339095
PubMed Web of Science ®Google Scholar
JärnerotGHertervigEFriis-LibyIInfliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled studyGastroenterology200512871805181115940615
PubMed Web of Science ®Google Scholar
SandbornWJvan AsscheGReinischWAdalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitisGastroenterology2012142225726522062358
PubMed Web of Science ®Google Scholar
LichtigerSPresentDHKornbluthACyclosporine in severe ulcerative colitis refractory to steroid therapyN Engl J Med199433026184118458196726
PubMed Web of Science ®Google Scholar
TravisSPSchnellDKrzeskiPReliability and initial validation of the ulcerative colitis endoscopic index of severityGastroenterology2013145598799523891974
PubMed Web of Science ®Google Scholar
YamamotoSNakaseHMikamiSLong-term effect of tacrolimus therapy in patients with refractory ulcerative colitisAliment Pharmacol Ther200828558959718549460
PubMed Web of Science ®Google Scholar
YamamotoTShimoyamaTUmegaeSMatsumotoKTacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis: a retrospective observational studyAliment Pharmacol Ther201643870571626762838
PubMed Web of Science ®Google Scholar
EndoKOnoderaMShigaHA comparison of short- and long-term therapeutic outcomes of infliximab- versus tacrolimus-based strategies for steroid-refractory ulcerative colitisGastroenterol Res Pract20162016316259526904108
PubMed Web of Science ®Google Scholar
ColombelJFSandbornWJGhoshSFour-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: data from ULTRA 1, 2, and 3Am J Gastroenterol2014109111771178025155227
PubMed Web of Science ®Google Scholar
AraiMNaganumaMSugimotoSThe ulcerative colitis endoscopic index of severity is useful to predict medium- to long-term prognosis in ulcerative colitis patients with clinical remissionJ Crohns Colitis201610111303130927194529
PubMed Web of Science ®Google Scholar
IkeyaKSugimotoKKawasakiSTacrolimus for remission induction in ulcerative colitis: mayo endoscopic subscore 0 and 1 predict long-term prognosisDig Liver Dis201547536537125682993
PubMedGoogle Scholar
HiraokaSKatoJSuzukiHYamamotoKReadministration of calcineurin inhibitors for ulcerative colitisAnn Pharmacother201246101315132123032660
PubMed Web of Science ®Google Scholar
BonovasSFiorinoGAlloccaMBiologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysisClin Gastroenterol Hepatol201614101385139727189910
PubMed Web of Science ®Google Scholar
KeaneJGershonSWiseRPTuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agentN Engl J Med2001345151098110411596589
PubMed Web of Science ®Google Scholar
EsteveMSaroCGonzález-HuixFSuarezFFornéMViverJMChronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxisGut20045391363136515306601
PubMed Web of Science ®Google Scholar
LongMDMartinCFPipkinCAHerfarthHHSandlerRSKappelmanMDRisk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel diseaseGastroenterology2012143239039922584081
PubMed Web of Science ®Google Scholar
KhanNAbbasAMLichtensteinGRLoftusEVJrBazzanoLARisk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort studyGastroenterology201314551007101523891975
PubMed Web of Science ®Google Scholar
AbitbolYLaharieDCosnesJNegative screening does not rule out the risk of tuberculosis in patients with inflammatory bowel disease undergoing anti-TNF treatment: a descriptive study on the GETAID cohortJ Crohns Colitis201610101179118527402916
PubMed Web of Science ®Google Scholar
OstermanMTSandbornWJColombelJFCrohn’s disease activity and concomitant immunosuppressants affect the risk of serious and opportunistic infections in patients treated with adalimumabAm J Gastroenterol2016111121806181527670599
PubMed Web of Science ®Google Scholar
OpelzGEffect of immunosuppressive therapy on graft half-life projections. The collaborative Transplant StudyTransplant Proc19993173133
Google Scholar
SugimotoSNaganumaMKiyoharaHClinical efficacy and safety of oral Qing-Dai in patients with ulcerative colitis: a single-center open-label prospective studyDigestion201693319320126959688
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Tacrolimus versus anti-tumor necrosis factor agents for steroid-refractory active ulcerative colitis based on the severity of endoscopic findings: a single-center, open-label cohort study

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Tacrolimus versus anti-tumor necrosis factor agents for steroid-refractory active ulcerative colitis based on the severity of endoscopic findings: a single-center, open-label cohort study

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date